Cost Minimization Analysis (CMA) of XELOX versus MFOLFOX6 in the treatment of colorectal cancer in a public hospital in Brazil
Introduction: Cancer worldwide is a public health problem with a perspective of 20 million new cases by 2025. Colorectal cancer (CRC) is ranked the third most incident tumor in the world and the fourth in Brazil. Hence the economic impact of care for these patients is significant. Objectives: The pu...
Saved in:
Main Authors: | Marcia Regina Godoy (Author), Sara Boscato (Author), Isabela Heineck (Author) |
---|---|
Format: | Book |
Published: |
Instituto Nacional de Assistência Farmacêutica e Farmacoeconomia,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost Minimization Analysis (CMA) of XELOX versus MFOLFOX6 in the treatment of colorectal cancer in an universitary hospital in Brazil
by: Sara Boscato, et al.
Published: (2023) -
Cost minimization analysis of two chemotherapy regimens in the treatment of colorectal cancer in a public reimbursement hospital in Brazil
by: Sara C. BOSCATO, et al.
Published: (2021) -
Severe proteinuria during the administration of bevacizumab plus mFOLFOX6 in a colorectal cancer patient after kidney transplantation: a case report
by: Ren Onodera, et al.
Published: (2020) -
Análise de custo-efetividade dos esquemas xelox e xelox mais bevacizumabe no tratamento do câncer colorretal metastático sob a perspectiva de um hospital público
by: Andrea Queiroz Ungari, et al.
Published: (2023) -
Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
by: Yufan Huang, et al.
Published: (2023)